Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201637 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1201158 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1200967 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1201167 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1200391 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1200921 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1201263 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1199870 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1201057 | 1.00 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1201577 | 0.98 | ESR1 (0.54) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253634-A9 | LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | Dai Nippon Printing Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110046366-A1 | LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME | DAI NIPPON PRINTING CO., LTD. (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2253634-A1 | LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | Dai Nippon Printing Co., Ltd. (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046366-A1 | LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME | PPOX, OR10J3, ORC3 | ESR1 3695/4885AKR1C4 856/4885AKR1C3 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.